Amgen Inc. has announced that its Phase 3 VESALIUS-CV clinical trial met its dual primary endpoints, demonstrating that Repatha® (evolocumab) significantly reduced the risk of major adverse cardiovascular events $(MACE)$ in individuals without a prior history of heart attack or stroke. The trial enrolled over 12,000 high-risk patients, most of whom were on high-intensity or moderate LDL-cholesterol lowering therapy, and followed them for a median of approximately 4.5 years. The primary endpoints included time to first occurrence of a composite of coronary heart disease death, heart attack, or ischemic stroke, as well as time to first occurrence of these events or any ischemia-driven arterial revascularization. The results were both statistically and clinically significant, with no new safety signals observed. These findings have already been announced by the company.